Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

AMED / Amedisys, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 9 AMEDISYS INC COMMON STOCK Cusip #023436108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #023436108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 269,450 Item 6: 0 Item 7: 998,874 Item 8: 0 Item 9: 998,874 Item 11: 2.943% Item 12: HC Cusip #023436108 Item 1: Reporting Person - Abigail P.

AMED / Amedisys, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 9 AMEDISYS INC COMMON STOCK Cusip #023436108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #023436108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 269,450 Item 6: 0 Item 7: 998,874 Item 8: 0 Item 9: 998,874 Item 11: 2.943% Item 12: HC Cusip #023436108 Item 1: Reporting Person - Abigail P.

Amedisys (AMED) Strong on Home Health, Margin Decline a Woe

2018-02-12 zacks
On Feb 9, we issued an updated research report on Amedisys, Inc. (AMED - Free Report) . The stock carries a Zacks Rank #3 (Hold). (32-0)

AMED / Amedisys, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-12 sec.gov
amedisysinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 7 )*       Name of issuer:  Amedisys Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  023436108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)

AMED / Amedisys, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-12 sec.gov
amedisysinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 7 )*       Name of issuer:  Amedisys Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  023436108     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)

AMED / Amedisys, Inc. / AMERICAN CENTURY INVESTMENT MANAGEMENT INC - SC 13G (Passive Investment)

2018-02-09 sec.gov
  United States Securities and Exchange Commission Washington, D.C.  20549         SCHEDULE 13G     Under the Securities Exchange Act of 1934     (Amendment No.   )*         AMEDISYS, INC. (Name of Issuer)     COMMON STOCK (Title of Class of Securities)     023436108 (CUSIP Number)       DECEMBER 31, 2017 (Date of Event Which Requires Filing of this Statement)             Check the appropriate box to designate the rule pursuant to which this Schedule is filed:     [ X ] Rule 13d-1(b) [     ] Rul

AMED / Amedisys, Inc. / AMERICAN CENTURY INVESTMENT MANAGEMENT INC - SC 13G (Passive Investment)

2018-02-09 sec.gov
  United States Securities and Exchange Commission Washington, D.C.  20549         SCHEDULE 13G     Under the Securities Exchange Act of 1934     (Amendment No.   )*         AMEDISYS, INC. (Name of Issuer)     COMMON STOCK (Title of Class of Securities)     023436108 (CUSIP Number)       DECEMBER 31, 2017 (Date of Event Which Requires Filing of this Statement)             Check the appropriate box to designate the rule pursuant to which this Schedule is filed:     [ X ] Rule 13d-1(b) [     ] Rul

Veeva Systems' Product Portfolio Strong, Competition Rife

2018-01-31 zacks
On Jan 30, we issued an updated research report on Veeva Systems (VEEV - Free Report) . Growing demand for cloud-based and vault applications and a diverse product portfolio are key positives. However, the company has been struggling against foreign exchange headwinds and intense competition in niche markets. (55-0)

Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?

2018-01-30 zacks
Shares of Abaxis, Inc. (ABAX - Free Report) scaled a new 52-week high of $78.53 on Jan 29, closing lower at $76. The company has gained 62.7% in the last six months, way higher than the broader industry’s gain of 13.9%. The stock has a market cap of $1.73 billion. Taking the stable stock performance into consideration, we expect Abaxis to scale higher in the coming quarters. Also, the company’s long-term expected earnings growth rate of 4% holds promise. (24-0)

Intuitive Surgical Gains on FDA Approvals, Competition Rife

2018-01-29 zacks
On Jan 26, we issued an updated research report on Intuitive Surgical, Inc. (ISRG - Free Report) . The stock has a Zacks Rank #3 (Hold). (47-1)

Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues

2018-01-26 zacks
Intuitive Surgical Inc (ISRG - Free Report) posted adjusted earnings of $2.54 per share in the fourth quarter of 2017, which beat the Zacks Consensus Estimate of $2.27 and improved 25.1% year over year. (37-0)

PerkinElmer (PKI) Beats on Q4 Earnings, Issues 2018 Guidance

2018-01-26 zacks
PerkinElmer Inc. (PKI - Free Report) reported fourth-quarter 2017 adjusted earnings of 97 cents per share, beating the Zacks Consensus Estimate of 94 cents. (38-0)

Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance

2018-01-24 zacks
Abbott (ABT - Free Report) reported fourth-quarter 2017 adjusted earnings from continuing operations of 74 cents per share, beating the Zacks Consensus Estimate by a penny. Earnings improved 13.8% year over year and met the high end of the company’s guided range of 72 cents to 74 cents. (17-0)

Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top

2018-01-24 zacks
Accuray Incorporated (ARAY - Free Report) reported a loss of 6 cents per share in the second quarter of fiscal 2018, 5 cents narrower than the Zacks Consensus Estimate and the year-ago figure. (32-0)

AngioDynamics (ANGO) Banks on Buyouts, Debt Level High

2018-01-24 zacks
On Jan 23, we issued an updated research report on AngioDynamics Inc. (ANGO - Free Report) . The stock has a Zacks Rank #3 (Hold). (34-0)


CUSIP: 023436108